Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.88 +0.14 (+0.54%)
Official Closing Price Updated: 7:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 Unstoppable Dividend Stocks to Buy Right Now
Investors will get great dividends and more with these stocks. 
Via The Motley Fool
Topics World Trade
Price Over Earnings Overview: Pfizer
 
Via Benzinga
My 5 Favorite Stocks to Buy Right Now
Not every ticker worth owning at this time has raced to an uncomfortably high price. 
Via The Motley Fool
Topics Artificial Intelligence
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market. 
Via Benzinga
This Is What Whales Are Betting On Pfizer
 
Via Benzinga
How Do Investors Really Feel About Pfizer?
 
Via Benzinga
Looking for the most active stocks in the S&P500 index on Thursday?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
My Top Dividend-Paying, Deep-Value Stock to Buy in August
You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock. 
Via The Motley Fool
Topics Earnings Intellectual Property
2 S&P 500 Stocks to Own for Decades and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Pfizer's yield is high, and so too is its payout ratio. 
Via The Motley Fool
3 Hyped Up Stocks That Fall Short
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
Intel, Nvidia, Twilio, Palo Alto Networks, Pfizer: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Intel continued its winning run amid news of new strategic investment, while Nvidia saw activity as traders geared up for its quarterly results due next week. 
Via Stocktwits
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
These S&P500 stocks are the most active in today's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year
These three businesses have been raising their payouts for at least 16 consecutive years. 
Via The Motley Fool
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Top Dividend Stocks to Buy on the Dip
These blue chip healthcare stocks could still deliver strong long-term returns. 
Via The Motley Fool
Topics Earnings Intellectual Property
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
3 Long-Term Dividend Buys You Can Get for Under $50
Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors 
Via MarketBeat
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Pfizer beat expectations last quarter and it raised its guidance. 
Via The Motley Fool
Topics World Trade
Celcuity Expenses Jump 81 Percent
Via The Motley Fool
Cautious Start On Dalal Street As Traders Eye Expiry, WPI Inflation Data; Muthoot Hits Record High, Infosys Gains on Versent Deal
Markets watch for the Trump–Putin meeting tomorrow that could impact Russia–Ukraine peace talks. Analysts see 24,600 as a make-or-break level for Nifty ahead of weekly expiry volatility. 
Via Stocktwits
Topics Economy Government
Most active S&P500 stocks in Wednesday's session
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year.... 
Via StockStory
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.